When certain mutations that may be present in tumours occur, especially in codons 12 and 13 of the KRAS gene, protein activation takes place regardless of the presence of EGFR, which is the target of some drugs for the treatment of this type of cancer, such as panitumumab and cetuximab. This evidence concerns the gene EGFR and cancer.